Literature DB >> 33201295

[Systemic treatment of advanced prostate cancer].

Alexander Kretschmer1, Tilman Todenhöfer2.   

Abstract

In recent years there have been substantial changes in the therapeutic landscape for systemic treatment of advanced prostate cancer (PCa), which resulted in a multitude of novel treatment options for different stages of the disease. In the current narrative review currently available treatment options for metastatic hormone-sensitive PCa as well as nonmetastatic castration-resistant PCa are presented. In addition, current treatment sequence options and targeted treatment in the stage of metastatic castration-resistant PCa are highlighted.

Entities:  

Keywords:  Androgen deprivation therapy; Androgen receptor inhibitors; Chemotherapy; Prostatic neoplasms; Targeted therapy

Mesh：

Substances：

Year:  2020        PMID： 33201295     DOI： 10.1007/s00120-020-01381-9

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  44 in total

1.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

2.  Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

Authors:  Alicia K Morgans; Yu-Hui Chen; Christopher J Sweeney; David F Jarrard; Elizabeth R Plimack; Benjamin A Gartrell; Michael A Carducci; Maha Hussain; Jorge A Garcia; David Cella; Robert S DiPaola; Linda J Patrick-Miller
Journal:  J Clin Oncol       Date:  2018-03-09       Impact factor: 44.544

3.  Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate.

Authors:  Alexander Kretschmer; Elio Mazzone; Francesco Barletta; Riccardo Leni; Isabel Heidegger; Igor Tsaur; Roderick C N van den Bergh; Massimo Valerio; Giancarlo Marra; Veeru Kasivisvanathan; Alexander Buchner; Christian G Stief; Alberto Briganti; Francesco Montorsi; Derya Tilki; Giorgio Gandaglia
Journal:  Eur Urol Focus       Date:  2020-09-19

4.  Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?

Authors:  Alexander Kretschmer; Tilman Todenhöfer
Journal:  Eur Urol Focus       Date:  2018-11-24

5.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Authors:  Gwenaelle Gravis; Jean-Marie Boher; Florence Joly; Michel Soulié; Laurence Albiges; Franck Priou; Igor Latorzeff; Remy Delva; Ivan Krakowski; Brigitte Laguerre; Frédéric Rolland; Christine Théodore; Gael Deplanque; Jean-Marc Ferrero; Stéphane Culine; Loïc Mourey; Philippe Beuzeboc; Muriel Habibian; Stéphane Oudard; Karim Fizazi
Journal:  Eur Urol       Date:  2015-11-21       Impact factor: 20.096

6.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

7.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Authors:  Gwenaelle Gravis; Karim Fizazi; Florence Joly; Stéphane Oudard; Franck Priou; Benjamin Esterni; Igor Latorzeff; Remy Delva; Ivan Krakowski; Brigitte Laguerre; Fréderic Rolland; Christine Théodore; Gael Deplanque; Jean Marc Ferrero; Damien Pouessel; Loïc Mourey; Philippe Beuzeboc; Sylvie Zanetta; Muriel Habibian; Jean François Berdah; Jerome Dauba; Marjorie Baciuchka; Christian Platini; Claude Linassier; Jean Luc Labourey; Jean Pascal Machiels; Claude El Kouri; Alain Ravaud; Etienne Suc; Jean Christophe Eymard; Ali Hasbini; Guilhem Bousquet; Michel Soulie
Journal:  Lancet Oncol       Date:  2013-01-08       Impact factor: 41.316

8.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

9.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

10.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Authors:  Christos E Kyriakopoulos; Yu-Hui Chen; Michael A Carducci; Glenn Liu; David F Jarrard; Noah M Hahn; Daniel H Shevrin; Robert Dreicer; Maha Hussain; Mario Eisenberger; Manish Kohli; Elizabeth R Plimack; Nicholas J Vogelzang; Joel Picus; Matthew M Cooney; Jorge A Garcia; Robert S DiPaola; Christopher J Sweeney
Journal:  J Clin Oncol       Date:  2018-01-31       Impact factor: 50.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.